Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours
- PMID: 1923534
Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours
Abstract
The p53 gene has been implicated as a tumour suppressor, with mutations occurring in many carcinomas, such as colon, breast and lung. We have sequenced exons 5, 7 and 8 containing conserved gene regions in the only available differentiated thyroid follicular carcinoma cell line and found a mutation at position 273, Arg----His, with no normal allele present. The same mutation was also present in DNA from the tumour of origin. However immunohistochemical analysis of 129 human thyroid tumours using a panel of p53 antibodies was unequivocally negative. Southern blotting in 20 cases failed to demonstrate any deletion or rearrangement, and direct genomic sequencing of 20 carcinomas showed normal DNA sequence for exons 5, 7 and 8. Thus p53 abnormalities may not be important in human thyroid carcinogenesis, in contrast to colon, breast and lung. However, the FTC 133 cell line was only established after 132 unsuccessful attempts with other differentiated thyroid follicular tumours. Since this line and the corresponding tumour of origin have a p53 mutation, we propose that p53 mutation may confer on thyroid follicular tumour cells the ability to grow in culture. This has potential applications for the future development of thyroid carcinoma cell lines.
Similar articles
-
FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.Clin Endocrinol (Oxf). 2000 Jun;52(6):749-57. Clin Endocrinol (Oxf). 2000. PMID: 10848880
-
Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.Cancer. 1998 Nov 15;83(10):2185-93. Cancer. 1998. PMID: 9827724
-
Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.J Exp Clin Cancer Res. 1999 Sep;18(3):363-7. J Exp Clin Cancer Res. 1999. PMID: 10606183
-
Genetic mutations in thyroid carcinoma.Minerva Endocrinol. 2009 Mar;34(1):11-28. Minerva Endocrinol. 2009. PMID: 19209125 Review.
-
Molecular analysis of mutations in thyroid tumors with TGGE.Exp Clin Endocrinol Diabetes. 1995;103(5):275-9. doi: 10.1055/s-0029-1211363. Exp Clin Endocrinol Diabetes. 1995. PMID: 8536054 Review.
Cited by
-
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.J Clin Invest. 1993 Apr;91(4):1753-60. doi: 10.1172/JCI116385. J Clin Invest. 1993. PMID: 8473515 Free PMC article.
-
Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.Endocrine. 2006 Aug;30(1):129-38. doi: 10.1385/ENDO:30:1:129. Endocrine. 2006. PMID: 17185801
-
The role of insulin-like growth factor-1 (IGF-1) in follicular thyroid cancer cell line CGTH W-1.In Vitro Cell Dev Biol Anim. 1995 Dec;31(11):817-21. doi: 10.1007/BF02634562. In Vitro Cell Dev Biol Anim. 1995. PMID: 8826082 No abstract available.
-
Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.Ann Surg. 2000 Mar;231(3):329-38. doi: 10.1097/00000658-200003000-00005. Ann Surg. 2000. PMID: 10714625 Free PMC article.
-
Absence of p53 mutation in Japanese patients with malignant thyroid lymphoma.J Endocrinol Invest. 1994 Nov;17(10):775-82. doi: 10.1007/BF03347774. J Endocrinol Invest. 1994. PMID: 7699210
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous